|
Viragen hat einen neuen Vorstandsvorsitzenden (CEO). Hier hat man sich wohl einen Profi für Umsatz- und Gewinnwachstum hereingeholt. Klingt nicht schlecht ... VIRAGEN NAMES NEW PRESIDENT AND CEO Growth of Multiferon™ Sales Program Named as Top Priority PLANTATION, FLORIDA – March 11, 2004 – Viragen, Inc. (AMEX: “VRA”) today announced the appointment of Charles A. Rice as President and Chief Executive Officer. He replaces Robert C. Salisbury who will continue to serve as a member of Viragen’s Board of Directors and as President and CEO of Viragen’s wholly-owned avian transgenics subsidiary, ViraGenics, Inc. Mr. Rice is a proven executive with 30 years of experience managing, directing and building stockholder value for companies in the life science industry. Most recently, he served as Group President of KV Pharmaceutical Company (NYSE: “KVa/KVb”) with responsibility for commercial activities. He previously served as President and CEO of Dey, Inc., a division of Germany’s Merck KGaA, where he developed and implemented strategies to create a rapidly growing and profitable business. He was credited for growing Dey’s sales 15-fold over a 10 year period and expanding its workforce to over 1,000 people. Under Mr. Rice’s leadership, Merck KGaA recognized Dey as one of its most profitable units. “With the addition of Charles Rice, we gain a skilled and seasoned executive determined to steer Viragen with focus and innovative vision which we expect will translate into realizing commercial opportunities,” stated Viragen’s Chairman, Carl N. Singer. “Charles has an outstanding track record of creating aggressive strategies while increasing stockholder value for rapidly growing organizations and his leadership should greatly contribute to drive the Company’s global initiatives and produce strong business results.” Commenting on his new role, Mr. Rice stated, “This is an opportunity to work with a solid core of talent and technology and to harness past achievements to take Viragen to the next level – as a leading manufacturer of human natural alpha interferon and respected developer of important new healthcare technologies. ” “While our top priority will be to improve sales of Multiferon, I am encouraged by Viragen’s pipeline of development products, plus the dramatic potential of Avian Transgenic Technology. I’m excited to join the Viragen team and I look forward to contributing to success for our stockholders as we move forward with our business plan.” Mr. Rice has a degree in Biology from Georgia College and extensive business education and experience through training and coursework at a variety of domestic and international universities, in addition to continuous participation in industry organizations. Mr. Singer added, “The Board thanks Robert Salisbury for his service as President and CEO and we look forward to his continued contributions on the VRA Board and steering ViraGenics. Bob accepted senior responsibility during a challenging period and under his direction we have accomplished many important goals. By building upon this foundation, we foresee a period of dynamic growth ahead.” Fraktal |
|
| aus der Diskussion: | Viragen - aktueller Artikel im Science Magazin |
| Autor (Datum des Eintrages): | Frakt@l (13.03.04 16:48:14) |
| Beitrag: | 109 von 128 (ID:12422123) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |